My Member
Message Center
trending topics
market reports
-
MEDICAL JAPAN 2025 OSAKA Returns to Showcase Global Innovations
2025-02-17
-
Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!
2023-09-01
-
US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight
2022-01-21
-
Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines
2022-01-21
-
Hong Kong researchers say they develop novel material able to kill COVID-19 virus
2022-01-14
-
10 million more Chinese doses on way for Kenya
2022-01-14
-
Sino-African ties on track for a brighter future
2022-01-07
-
Efforts urged to boost COVID-19 vaccine production capacity in poor countries
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
Four Chinese COVID-19 vaccines undergoing phase-3 clinical trials
BEIJING, Aug. 28 (Xinhua) -- Four Chinese COVID-19 vaccine candidates have started international phase-3 clinical trials, according to the State Council joint prevention and control mechanism against COVID-19.
2020-09-01Innovation -
Chinese researchers develop new diagnostic method for ovarian cancer
Chinese researchers have developed a non-invasive method to differentiate ovarian cancer subtypes, which could help improve therapeutic plans, according to the Chinese Academy of Sciences (CAS).
2020-08-20Innovation -
China's phase 2 trial finds COVID-19 vaccine safe, inducing immune response -- The Lancet
"The phase 2 trial adds further evidence on safety and immunogenicity in a large population than the phase 1 trial. This is an important step in evaluating this early-stage experimental vaccine and phase 3 trials are now underway."
2020-07-22Innovation -
Domestic coronavirus vaccines perform well in clinical trials
Sinopharm upgrades factory capacity, aiming for 200 million doses a year
2020-06-01Innovation -
China's COVID-19 vaccine trial shows promising results -- The Lancet
The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement.
2020-05-25Innovation